Verrica Pharmaceuticals (VRCA) Short Interest Ratio & Short Volume $5.47 -0.27 (-4.70%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.47 0.00 (0.00%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Verrica Pharmaceuticals Short Interest DataVerrica Pharmaceuticals (VRCA) has a short interest of 149,800 shares, representing 2.99% of the float (the number of shares available for trading by the public). This marks a -32.28% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.2, indicating that it would take 3.2 days of the average trading volume of 49,586 shares to cover all short positions.Current Short Interest149,800 sharesPrevious Short Interest221,200 sharesChange Vs. Previous Month-32.28%Dollar Volume Sold Short$843.37 thousandShort Interest Ratio3.2 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares9,450,000 sharesFloat Size5,010,000 sharesShort Percent of Float2.99%Today's Trading Volume50,701 sharesAverage Trading Volume49,586 sharesToday's Volume Vs. Average102% Short Selling Verrica Pharmaceuticals? Sign up to receive the latest short interest report for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVRCA Short Interest Over TimeVRCA Days to Cover Over TimeVRCA Percentage of Float Shorted Over Time Verrica Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025149,800 shares $843.37 thousand -32.3%3.0%3.2 $5.63 7/15/2025221,200 shares $1.77 million +1,164.0%N/A5.2 $7.98 6/30/202517,500 shares $9.28 thousand -99.4%0.4%0.1 $0.53 6/15/20252,970,000 shares $1.85 million +30.8%7.0%9.2 $0.62 5/31/20252,270,000 shares $1.14 million -27.9%8.7%5.9 $0.50 5/15/20253,150,000 shares $2.02 million +16.2%12.0%7.9 $0.64 4/30/20252,710,000 shares $1.26 million -4.6%N/A6.9 $0.46 4/15/20252,840,000 shares $1.40 million -0.4%10.9%7.3 $0.49 3/31/20252,850,000 shares $1.26 million +28.4%10.9%7 $0.44 3/15/20252,220,000 shares $1.19 million +9.4%8.5%4.9 $0.54 Get the Latest News and Ratings for VRCA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/20252,030,000 shares $1.32 million +2.0%7.8%4.6 $0.65 2/15/20251,990,000 shares $1.47 million -1.5%7.6%3.8 $0.74 1/31/20252,020,000 shares $1.31 million +11.0%N/A3.3 $0.65 1/15/20251,820,000 shares $1.21 million -6.7%N/A2.6 $0.66 12/31/20241,950,000 shares $1.37 million -2.5%N/A2.7 $0.70 12/15/20242,000,000 shares $1.52 million -34.2%N/A2.2 $0.76 11/30/20243,040,000 shares $3.89 million -32.6%N/A3.5 $1.28 11/15/20244,510,000 shares $3.76 million +3.2%16.6%4.7 $0.83 10/31/20244,370,000 shares $6.12 million -3.5%16.1%4 $1.40 10/15/20244,530,000 shares $6.30 million +24.8%17.4%4.7 $1.39 9/30/20243,630,000 shares $5.26 million +11.7%13.9%3.9 $1.45 9/15/20243,250,000 shares $6.40 million +9.1%12.5%4.7 $1.97 8/31/20242,980,000 shares $7.00 million -28.9%11.5%4.6 $2.35 8/15/20244,190,000 shares $12.19 million +13.6%16.2%9.3 $2.91 7/31/20243,690,000 shares $24.32 million -6.8%14.3%15.4 $6.59 7/15/20243,960,000 shares $33.15 million +1.3%15.4%17.1 $8.37 6/30/20243,910,000 shares $28.50 million +9.5%15.2%18 $7.29 6/15/20243,570,000 shares $28.99 million +0.9%13.9%16.5 $8.12 5/31/20243,540,000 shares $30.13 million -7.8%13.7%18.2 $8.51 5/15/20243,840,000 shares $34.94 million +6.1%14.9%20.2 $9.10 4/30/20243,620,000 shares $25.21 million -5.7%14.1%23.6 $6.97 4/15/20243,840,000 shares $26.57 million -8.1%15.1%28.3 $6.92 3/31/20244,180,000 shares $24.75 million -5.0%16.5%28.2 $5.92 3/15/20244,400,000 shares $21.12 million -0.7%17.4%22.4 $4.80 2/29/20244,430,000 shares $23.35 million +1.1%17.4%4.1 $5.27 2/15/20244,380,000 shares $24.35 million -1.1%17.3%4.1 $5.56 1/31/20244,430,000 shares $25.03 million -20.2%17.7%4.1 $5.65 1/15/20245,550,000 shares $31.75 million +5.3%22.1%5.1 $5.72 12/31/20235,270,000 shares $38.58 million +44.4%21.0%4.9 $7.32 12/15/20233,650,000 shares $22.23 million -8.5%14.6%3.4 $6.09Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 11/30/20233,990,000 shares $14.68 million -6.3%15.9%25 $3.68 11/15/20234,260,000 shares $13.50 million +1.2%17.0%23.9 $3.17 10/31/20234,210,000 shares $15.49 million -2.3%16.7%21.7 $3.68 10/15/20234,310,000 shares $15.73 million -3.8%17.1%15.1 $3.65 9/30/20234,480,000 shares $17.40 million -9.3%17.8%11.8 $3.89 9/15/20234,940,000 shares $20.01 million +1.9%19.6%12.6 $4.05 8/31/20234,850,000 shares $22.07 million +7.5%19.3%11.5 $4.55 8/15/20234,510,000 shares $22.50 million +11.1%17.8%11.1 $4.99 7/31/20234,060,000 shares $23.71 million +34.4%16.0%10.7 $5.84 7/15/20233,020,000 shares $20.20 million +3.8%12.0%9.4 $6.69 6/30/20232,910,000 shares $16.79 million +33.5%11.5%13.3 $5.77 6/15/20232,180,000 shares $13.67 million +6.9%8.6%10.6 $6.27 5/31/20232,040,000 shares $11.57 million +14.6%8.1%13.4 $5.67 5/15/20231,780,000 shares $10.86 million +21.1%7.1%10.9 $6.10 4/30/20231,470,000 shares $9.07 million +55.7%5.9%7.6 $6.17 4/15/2023944,100 shares $5.85 million +60.7%3.8%4.9 $6.20 3/31/2023587,500 shares $3.82 million +94.8%2.4%3 $6.50 3/15/2023301,600 shares $2.01 million +24.8%1.2%1.7 $6.65 2/28/2023241,600 shares $1.87 million -7.5%1.0%1.4 $7.75 2/15/2023261,200 shares $1.97 million +12.1%1.1%1.6 $7.54 1/31/2023233,000 shares $1.08 million -50.7%1.0%1.7 $4.62 1/15/2023472,500 shares $2.29 million -18.4%2.0%4.2 $4.85 12/30/2022579,300 shares $1.59 million -7.9%2.4%5.9 $2.75 12/15/2022629,000 shares $1.98 million -4.2%2.6%8.1 $3.14 11/30/2022656,300 shares $2.13 million -5.7%2.7%6.6 $3.25 11/15/2022695,800 shares $1.59 million +6.0%2.9%7.1 $2.28 10/31/2022656,300 shares $1.63 million +7.0%2.7%6.5 $2.49 10/15/2022613,200 shares $1.67 million -1.9%2.6%5.7 $2.73 9/30/2022625,100 shares $1.83 million -19.6%2.6%4.5 $2.92 9/15/2022777,900 shares $2.96 million -9.8%3.2%2.4 $3.80 8/31/2022862,400 shares $3.38 million -10.1%3.7%2.6 $3.92 8/15/2022958,800 shares $3.75 million -8.7%4.1%1.8 $3.91 7/31/20221,050,000 shares $3.31 million +5.0%7.0%1.9 $3.15 7/15/20221,000,000 shares $3.21 million -16.7%6.6%1.8 $3.21 6/30/20221,200,000 shares $2.30 million -30.2%8.0%2.2 $1.92 6/15/20221,720,000 shares $3.82 million -5.0%11.1%4.6 $2.22 5/31/20221,810,000 shares $3.49 million -0.6%11.7%5.6 $1.93 5/15/20221,820,000 shares $10.30 million +3.4%11.7%15.3 $5.66 4/30/20221,760,000 shares $11.56 million +8.6%11.3%22.4 $6.57 4/15/20221,620,000 shares $12.83 million +5.2%10.4%23.9 $7.92 3/31/20221,540,000 shares $12.49 million +0.7%9.9%26.6 $8.11 3/15/20221,530,000 shares $12.19 million +2.0%9.9%27 $7.97 2/28/20221,500,000 shares $12.57 million -6.3%9.7%24 $8.38 2/15/20221,600,000 shares $13.41 million +2.6%10.3%23.8 $8.38 1/31/20221,560,000 shares $12.78 million +6.9%11.1%24.5 $8.19 1/15/20221,460,000 shares $12.15 million +2.1%11.1%23.3 $8.32 12/31/20211,430,000 shares $13.10 million +2.1%10.9%23.4 $9.16 12/15/20211,400,000 shares $13.19 million +6.9%10.6%20.5 $9.42 11/30/20211,310,000 shares $13.56 million No Change9.9%11.5 $10.35 11/15/20211,310,000 shares $15.77 million -0.8%9.9%10.6 $12.04Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 10/29/20211,320,000 shares $16.62 million -2.9%10.0%10.5 $12.59 10/15/20211,360,000 shares $18.17 million -8.1%10.3%11 $13.36 9/30/20211,480,000 shares $18.50 million -21.3%11.2%12.1 $12.50 9/15/20211,880,000 shares $22.15 million -2.1%14.2%15.4 $11.78 8/31/20211,920,000 shares $21.50 million -3.0%14.6%24.6 $11.20 8/13/20211,980,000 shares $21.27 million -2.9%15.1%24.9 $10.74 7/30/20212,040,000 shares $21.83 million No Change15.6%24.2 $10.70 7/15/20212,040,000 shares $21.11 million -1.5%14.0%22.3 $10.35 6/30/20212,070,000 shares $23.39 million +2.0%14.2%21.1 $11.30 6/15/20212,030,000 shares $23.97 million +24.5%13.9%18.6 $11.81 5/28/20211,630,000 shares $18.35 million +8.0%11.1%14.4 $11.26 5/14/20211,510,000 shares $17.62 million +1.3%10.3%14.4 $11.67 4/30/20211,490,000 shares $19.37 million +4.9%10.2%14.1 $13.00 4/15/20211,420,000 shares $19.31 million +17.4%9.7%12.6 $13.60 3/31/20211,210,000 shares $16.55 million +8.0%8.8%10.9 $13.68 3/15/20211,120,000 shares $18.96 million -24.3%7.7%11.2 $16.93 2/26/20211,480,000 shares $21.02 million +0.7%10.8%17.3 $14.20 2/12/20211,470,000 shares $21.42 million -4.6%10.7%19.1 $14.57 1/29/20211,540,000 shares $18.26 million -3.8%11.2%19 $11.86 1/15/20211,600,000 shares $18.86 million -3.6%12.6%20.8 $11.79 12/31/20201,660,000 shares $19.87 million -2.9%13.0%25.5 $11.97 12/15/20201,710,000 shares $16.86 million -8.1%13.5%24.8 $9.86 11/30/20201,860,000 shares $17.52 million +8.1%14.7%24.2 $9.42 10/30/20201,860,000 shares $14.17 million -21.2%14.7%10.9 $7.62 10/15/20202,360,000 shares $19.33 million -7.5%18.7%11.8 $8.19 9/30/20202,550,000 shares $19.74 million +38.6%20.2%11.3 $7.74 9/15/20201,840,000 shares $16.50 million +5.8%14.6%7.7 $8.97 8/31/20201,740,000 shares $15.99 million -3.9%13.8%7.6 $9.19 VRCA Short Interest - Frequently Asked Questions What is Verrica Pharmaceuticals' current short interest? Short interest is the volume of Verrica Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 149,800 shares of VRCA short. 2.99% of Verrica Pharmaceuticals' shares are currently sold short. Learn More on Verrica Pharmaceuticals' current short interest. What is a good short interest ratio for Verrica Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRCA shares currently have a short interest ratio of 3.0. Learn More on Verrica Pharmaceuticals's short interest ratio. What is a good short interest percentage for Verrica Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.99% of Verrica Pharmaceuticals' floating shares are currently sold short. Is Verrica Pharmaceuticals' short interest increasing or decreasing? Verrica Pharmaceuticals saw a drop in short interest in July. As of July 31st, there was short interest totaling 149,800 shares, a drop of 32.3% from the previous total of 221,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Verrica Pharmaceuticals' float size? Verrica Pharmaceuticals currently has issued a total of 9,450,000 shares. Some of Verrica Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Verrica Pharmaceuticals currently has a public float of 5,010,000 shares. How does Verrica Pharmaceuticals' short interest compare to its competitors? 2.99% of Verrica Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Verrica Pharmaceuticals: Monopar Therapeutics Inc. (3.43%), ProQR Therapeutics N.V. (0.39%), AC Immune (2.44%), Aerovate Therapeutics, Inc. (21.72%), Contineum Therapeutics, Inc. (1.97%), Voyager Therapeutics, Inc. (6.18%), Heron Therapeutics, Inc. (24.43%), Lyell Immunopharma, Inc. (3.29%), Aclaris Therapeutics, Inc. (6.40%), Innate Pharma S.A. Sponsored ADR (0.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Verrica Pharmaceuticals stock? Short selling VRCA is an investing strategy that aims to generate trading profit from Verrica Pharmaceuticals as its price is falling. VRCA shares are trading down $0.27 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verrica Pharmaceuticals? A short squeeze for Verrica Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRCA, which in turn drives the price of the stock up even further. How often is Verrica Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRCA, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies MNPR Short Squeeze PRQR Short Squeeze ACIU Short Squeeze AVTE Short Squeeze CTNM Short Squeeze VYGR Short Squeeze HRTX Short Squeeze LYEL Short Squeeze ACRS Short Squeeze IPHA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VRCA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access